CTGT holds a New York State Department of Health Clinical Laboratory Permit to perform molecular genetic testing on patients from New York State. Currently, our osteogenesis imperfecta tests have been approved and may be run on all New York state patients. For all other tests, a Restricted Laboratory Permit must be obtained before CTGT can perform the test on a New York state patient. Additional tests for New York state patients will be added when they are approved by the New York State Department of Health.

To order osteogenesis imperfecta testing on New York state patients, a Patient Consent Form must be completed and submitted to CTGT with the patient specimen.

Additionally, CTGT’s standard Test Requisition Form should be completed and submitted with the patient specimen.

The following panels are approved for New York State patients:

(Please note: The MBTPS2 and XYLT2 genes are not included in the New York State Approved test.)

Additionally, the following osteogenesis imperfecta related genes are approved for single gene testing and targeted variant/known familial mutation testing:



To perform any other test on a New York State patient, a Non-Permitted Laboratory Test Request Approval Form must be completed and submitted to the New York State Department of Health. If the request is approved, CTGT can perform the test for that patient. Please submit a copy of the approval letter and the CTGT standard Test Requisition Form with the patient specimen. For further information on the approval process, please see the NYS Instructions and NYS Non-Permitted Laboratory Test Request Approval Form.

NYS Instructions                            NYS Non-Permitted Laboratory Test Request Approval Form

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

What's New

April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More
October 13, 2021

CTGT.net: A New Website Experience

We've refreshed our look and feel to better meet your needs. 

CTGT's new website is not only user-friendly but also provides more advanced test search capabilities, additional methodologies, and a clean design suited for multi-platform usage.

Read More
September 28, 2021

9 New Tests for Genetic Carrier Screening Panels

CTGT is now offering 9 NEW tests for Genetic Carrier Screening. 
Read More
September 25, 2021

New York State Clinical Laboratory Permit Approval

CTGT is proud to announce that its CLIA licensed and CAP-accredited Pennsylvania laboratory has earned a New York State Department of Health clinical laboratory permit to perform genetic testing for patients residing within the state of New York. 
Read More